

SenzaGen presents and hosts a panel discussion at the SOT Annual Meeting & ToxExpo 2024

Lund, March 6, 2024

SenzaGen, which develops and sells non-animal chemical tests based on genomics and machine learning, announces today that the company will hold presentations and organize a round-table discussion at the SOT Annual Meeting & ToxExpo, the world's largest conference in toxicology, taking place in Salt Lake City, USA, from March 10 to 14, 2024.

The conference is organized by the American organization The Society of Toxicology and is expected to gather around 5,000 scientists and toxicologists from all over the world.

During the event, SenzaGen's team and collaborative partners will present the GARD® test platform for *in vitro* skin sensitization, emphasizing its broad applicability, relevance for medical devices, and ability to provide quantitative information about safe dose levels.

Moreover, SenzaGen will facilitate a panel discussion on the evolving trends in skin sensitization and *in vitro* testing. The expert panel will include representatives from L'Oréal, the American Research Institute for Fragrance Materials (RIFM), and the ISO working group for skin irritation and skin sensitization.

Scientific program

March 12, 9:00–10:00

Presentation and round-table discussion on new alternative methods (NAMs) and industry trends

Advancing NAMs for Skin Sensitization Testing: Medical Devices and Quantitative Potency Assessment

Expert Panel:

- Dr Nathalie Alépée, Research Scientific Officer, L'Oréal Research & Innovation
- Dr Isabelle Lee, Senior Scientist, Research Institute for Fragrance Materials, Inc. (RIFM)
- Dr Christian Pellevoisin, Toxicologist, Urbilateria, Convenor of the WG8 skin irritation and sensitization of the ISO/TC194 for biocompatibility of medical devices
- Dr Henrik Johansson, Chief Scientist, SenzaGen

March 11–12

Posters on GARD®

Spotlight on PoD, NESILs, product development and CE-marking of Medical Devices

Joint poster with L'Oréal

P739 #4190 | *Improved Confidence of Quantitative Sensitizing Potency Assessment for Point of Departure Using GARD@skin Dose-Response*



Joint poster with Sonova

P487 #3362 | *Unveiling skin sensitizing potential: case studies on biocompatible material development utilizing the in vitro GARD@skin Medical Device assay*

Joint poster with Duearity

P480 #3355 | *Regulatory approval of medical devices according to MDR using in vitro data from GARD@skin Medical Device for skin sensitization assessment*

Joint poster presented by RIFM

P318 #3205 | *Determining a point of departure for skin sensitization potency and quantitative risk assessment of fragrance ingredients using the GARD@skin Dose-Response assay*

Joint poster presented by IFF

P762 #4213 | *A Next Generation Risk Assessment (NGRA) Framework to conduct Quantitative Risk Assessment (QRA2) to determine safe use levels of fragrance ingredients in cosmetic products*

Joint poster presented by Inotiv

P738 #4189 | *Testing of Regulatory-Relevant Chemicals for Skin and Respiratory Sensitization Hazard*

Visit us at booth #732

Our team of GARD® experts will be on hand at booth #732 to engage in discussions and answer any inquiries regarding *in vitro* toxicology.

SOT webpage

For additional details on the conference, please refer to the official website of the [63rd SOT Annual Meeting & ToxExpo](#).

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB

Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications

Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44



About us

SenzaGen is a corporate group that aims to be a leader in *in vitro* science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.

Attachments

[SenzaGen presents and hosts a panel discussion at the SOT Annual Meeting & ToxExpo 2024](#)